Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist.
Article
Dans Anglais
| IMSEAR
| ID: sea-39090
ABSTRACT
PURPOSE:
To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK).DESIGN:
A prospective randomized controlled clinical study.PARTICIPANTS:
Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital. INTERVENTION Patients received two drops of ketorolac tromethamine in one eye immediately after surgery. MAIN OUTCOMEMEASURES:
Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours.RESULTS:
There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes.CONCLUSIONS:
Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Astigmatisme
/
Mesure de la douleur
/
Femelle
/
Humains
/
Mâle
/
Anti-inflammatoires non stéroïdiens
/
Études prospectives
/
Adulte
/
Kétorolac trométhamine
/
Kératomileusis in situ avec laser excimère
Type d'étude:
Essai clinique contrôlé
/
Étude observationnelle
langue:
Anglais
Année:
2001
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS